Anti–vascular endothelial growth factor agents in the treatment of retinal disease: from bench to bedside

PA Campochiaro, LP Aiello, PJ Rosenfeld - Ophthalmology, 2016 - Elsevier
The association of retinal hypoxia with retinal neovascularization has been recognized for
decades, causing Michaelson to postulate in 1948 that a factor secreted by hypoxic retina …

[HTML][HTML] A brief history of anti-VEGF for the treatment of ocular angiogenesis

LA Kim, PA D'Amore - The American journal of pathology, 2012 - Elsevier
In 1994, The American Journal of Pathology published a key article reporting that hypoxic
retina produces vascular endothelial growth factor (VEGF), suggesting a role for VEGF in …

Treatment of retinal diseases with VEGF antagonists

RO Schlingemann, AN Witmer - Progress in brain research, 2009 - Elsevier
Diabetic retinopathy (DR) and age-related macular degeneration (AMD) are the most
prevalent causes of blindness in the Western world. The pathogenesis of neovascularization …

Anti‐VEGF therapy and the retina: an update

V Tah, HO Orlans, J Hyer, E Casswell… - Journal of …, 2015 - Wiley Online Library
Ocular angiogenesis and macular oedema are major causes of sight loss across the world.
Aberrant neovascularisation, which may arise secondary to numerous disease processes …

Development of anti‐VEGF therapies for intraocular use: a guide for clinicians

PA Keane, SR Sadda - Journal of ophthalmology, 2012 - Wiley Online Library
Angiogenesis is the process by which new blood vessels form from existing vessel networks.
In the past three decades, significant progress has been made in our understanding of …

Antiangiogenic therapy for ischemic retinopathies

M Al-Latayfeh, PS Silva, JK Sun… - Cold Spring …, 2012 - perspectivesinmedicine.cshlp.org
Neovascularization is a common pathological process in various retinal vascular disorders
including diabetic retinopathy (DR), age-related macular degeneration (AMD) and retinal …

Intravitreal anti-vascular endothelial growth factor therapies for retinal disorders

A Hang, S Feldman, AP Amin, JAR Ochoa, SS Park - Pharmaceuticals, 2023 - mdpi.com
Vascular endothelial growth factors (VEGFs) are key mediator of retinal and choroidal
neovascularization as well as retinal vascular leakage leading to macular edema. As such …

Anti-vascular endothelial growth factor therapy for diabetic macular edema

DS Boyer, JJ Hopkins, J Sorof… - … in endocrinology and …, 2013 - journals.sagepub.com
Diabetes mellitus is a serious health problem that affects over 350 million individuals
worldwide. Diabetic retinopathy (DR), which is the most common microvascular complication …

Diabetic macular edema

GE Lang - Ophthalmologica, 2012 - karger.com
Diabetic retinopathy is one of the major complications of diabetes mellitus and a leading
cause of visual loss. Diabetic macular edema (DME) is an ocular manifestation of the …

Anti-VEGF therapy: higher potency and long-lasting antagonism are not necessarily better

A Usui-Ouchi, M Friedlander - The Journal of Clinical …, 2019 - Am Soc Clin Investig
The “golden years” are much less so if you lose your central vision to neovascular age-
related macular degeneration (AMD). Approximately 15 out of 1000 individuals over age 75 …